Gender characteristics of lipid correction and anti-remodelling effects of various lipid-lowering therapies in patients with metabolic syndrome
https://doi.org/10.21518/2079-701X-2013-6-106-110
Abstract
The article tells about a comparative evaluation of lipid correction and remodeling effects of statin monotherapy and its fixed combination with ezetimibe on the left ventricular myocardium, intima-media thickness (IMT) and C-reactive protein (CRP) in men and women with metabolic syndrome (MS). The combination simvastatin + ezetimibe was more effective in women, resulting both in greater number of patients achieving the target level of LDL cholesterol, and the degree of positive change in lipid profile and IMT. Hypolipidemic and anti-inflammatory effects are comparable in men and women with MS who took simvastatin. Therapy with simvastatin or simvastatin + ezetimibe has a more marked anti-remodelling effect in women compared with men.
About the Authors
V. V. Skibitskiy
Kuban State Medical University Russia's Ministry of Health
Russian Federation
Russian Federation
Z. T. Sokaeva
Kuban State Medical University Russia's Ministry of Health
Russian Federation
Russian Federation
A. V. Fendrikova
Kuban State Medical University Russia's Ministry of Health
Russian Federation
Russian Federation
References
1. Оганов Р.Г., Масленникова Р.Я. Гендерные различия кардиоваскулярной патологии. Кардиоеаскулярная терапия и профилактика, 2012;11(4):101-104.
2. Шляхто Е.В., Конрати А.О. Эпидемиология метаболического синдрома в различных регионах. Артериальная гипертензия, 2007;13(2):95-112.
3. Regitz-Zagrosek V.et al. Gender differences in the metabolic syndrome and their role for cardiovascular disease. Clin Res Cardiol., 2006;95:136-147.
4. Глезер М.Г. Антигипертензивная терапия и сахарный диабет. Проблемы женского здоровья, 2007;2(2):40-56.
5. Barrett-Connor E, Ferrara A. Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study. Diabetes Care, 1998;21(8):1236-1239.
6. Takahashi K, Hirocazu B, Ken'ichi I et al. Atsushi N, Shuhei Y, Shotai K. Sex differences in the association between metabolic syndrome and the risk of ischemic stroke. Japanese Journal of Stroke, 2006;28(4):527-530.
7. ESC/ EAS Guidelines for the management of dyslipidemias. European Heart Journal, 2011;32:1769-1818.
8. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации. М., 2012;4: 2-35.
9. Vrecer M, Turk S, Drinovec J, Mrhar A. Use of statins in primary and secondary revention of coronary heart disease and ischaemic stroke. Meta-analysis of randomized trials. Int J Clin Pharmacol Ther., 2003;41:567-577.
10. Betteridge D, Gibson M. Effect of rosuvastatin and atorvastatin on LDL-C and CRP levels in patients with type 2 diabetes: results of the ANDROMEDA study. Atherosclerosis, 2004;5:107.
11. Crouse JR III, Raichlen JS, Riley WA et al. Intima-Media Thickness in Low-Risk ndividuals With Effect of Rosuvastatin on Progression of Carotid Subclinical Atherosclerosis: The METEOR Trial.JAMA, 2007;297 (12):1344-1353.
12. Ridker PM, Danielson E, Fonseca FA et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med, 2008;359:2195-2207.
13. Ballantyne CM, Abate N, Yuan Z et al. Dose-Comparison Study of the Combination of Ezetimibe and Simvastatin (Vytorin) Versus Atorvastatin in Patients With Hypercholesterolemia: The Vytorin Versus Atorvastatin (VYVA) Study. Amer. HeartJ., 2005;149:464-473.
14. Ballantyne CM, Weiss R, Moccetti T et al. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Amer. J. Cardiol, 2007;99(5):673-680.
15. Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). М., 2010;5-33.
16. Диагностика и лечение метаболического синдрома. Российские рекомендации. М., 2009;2-21.
17. Radhakrishnan AR, Gylling Н, Tatu AМ. Cholesterol Absorption, Synthesis, and Fecal Output in Postmenopausal Women With and Without Coronary ArteryDisease. Cholesterol synthesis prevails over absorption in metabolic syndrome. International Journal of Vascular Medicine, 2007;149(6):310-316.
18. Bosner MS, Lange LG, Stenson WF, Ostlund RE. Percent cholesterol absorption in normal women and men quantified with duel stable isotope tracers and negative ion mass spectrometry. J Lipid Res, 1999;40:302-308.
19. Miura Shinichiro, Saku Keijiro. Ezetimibe, a selective inhibitor of the transport of cholesterol. Inter. Med., 2008;47:1165-1170.
20. Altmann SW, Davis HR, Zhu LJ et al. Niemann-Pick Cl like 1 protein is critical for intestinal cholesterol absorption. Science, 2000,303:1201-1204.
21. Garcia-Calvo M, Lisnock J, Bull HG et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci USA, 2005;102:8132-8137.
22. Turley SD. Dietary cholesterol and the mechanisms of cholesterol absorption. Eur Heart J, 1999;1:29-35.
23. Fleg JL, Mete M, Howard BV et al. Effect of Statins Alone Versus Statins Plus Ezetimibe on Carotid Atherosclerosis in Type 2 Diabetes The SANDS (Stop Atherosclerosis in Native Diabetics Study) Trial. J Am Coll Cardiol, 2008;52:2198-2205.
24. Rossebo AB, Pedersen TR, Boman K et al. Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis. N Engl J Med, 2008;359:1343-1356.
25. Delbosc S, Cristol JP, Descomps B, Mimran A, Jover B. Simvastatin prevents angiotensin II–induced cardiac alteration and oxidative stress. Hypertension, 2002;40:142-147.
26. Furman C, Copin C, Kandoussi M еt al. Rosuvastatin reduces MMP-7 secretion by human monocyte-derived macrophages: potential relevance to atherosclerotic plaque stability. Atherosclerosis, 2004;174:93-98.
27. Скибицкий В.В., Прасолова С.А., Фендрикова А.В. Эффективность применения розувастатина в комплексной терапии больных с систолической формой хронической сердечной недостаточности. Кубанский научный медицинский вестник, 2011;6(129):143-148.
28. Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т. Хроническая сердечная недостаточность. Избранные лекции по кардиологии. М., 2006. С. 432.
29. Copin C, Davidson R, McTaggiart F et al. Rosuvastatin reduces MMP-9 and MMP-7 secretion by human monocyte-derived macrophages. Int J Clin Pract, 2002;124-127.
30. Pearson TA, Ballantyne CM, Veltri E, et al. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy. Am J Cardiol, 2009;103:369-374.
31. Gomez-Garre D, Munoz-Pacheco P, Gonzales-Rubio ML et al. Ezetimibe reduces plaque inflammation in a model of atherosclerosis in rabbits and inhibits monocyte transmigration in addition to its lipid-lowering effect. Br J Pharmacol, 2009;156:1218-1227.
Review
For citations:
Skibitskiy VV, Sokaeva ZT, Fendrikova AV. Gender characteristics of lipid correction and anti-remodelling effects of various lipid-lowering therapies in patients with metabolic syndrome. Meditsinskiy sovet = Medical Council. 2013;(6):106-110. (In Russ.) https://doi.org/10.21518/2079-701X-2013-6-106-110
Views:
396
Email this article 